Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Yngvar Nilssen"'
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Lars Fjellbirkeland, Åslaug Helland, Bjørn Møller, Sissel Gyrid Freim Wahl, Steinar Solberg
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The main focus on the characteristics of malignant lung tumours has been the size, position within the lobe, and infiltration into neighbouring structures. The aim of this study was to investigate the distribution and characterist
Externí odkaz:
https://doaj.org/article/5875a883bc094aa79f00eb35ae725d73
Autor:
Afaf Al-Rammahy, Elin Anita Fadum, Yngvar Nilssen, Inger Kristin Larsen, Erlend Hem, Berit Horn Bringedal
Publikováno v:
Research in Health Services & Regions, Vol 3, Iss 1, Pp 1-10 (2024)
Abstract Objectives This study aimed to examine disparities in cancer incidence, stage at diagnosis, and survival rates across districts with differences in education levels in Oslo, Norway. Methods Aggregated data from the Cancer Registry of Norway
Externí odkaz:
https://doaj.org/article/5051186608ee4433afebe6ae8e032880
Autor:
Knut Eirik Dalene, Simon Lergenmuller, Erik R. Sund, Laila A. Hopstock, Trude Eid Robsahm, Yngvar Nilssen, Wenche Nystad, Inger Kristin Larsen, Inger Ariansen
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Noncommunicable diseases (NCDs) are a leading cause of premature death globally and have common preventable risk factors. In Norway, the NCDNOR-project aims at establishing new knowledge in the prevention of NCDs by combining information fro
Externí odkaz:
https://doaj.org/article/aa2d8e7989e34f8bb8c0023254ae94b5
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Marianne G. Guren, Erik Skaaheim Haug, Bjørn Naume, Ellen Schlichting, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer
Externí odkaz:
https://doaj.org/article/f1e88728779a43d0803e29d8f28fd44c
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background International differences in survival among colorectal cancer (CRC) patients may partly be explained by differences in emergency presentations (EP), waiting times and access to treatment. Methods CRC patients registered in 2015–
Externí odkaz:
https://doaj.org/article/a8abc6856f7b48569992236afb816fb8
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Morten Tandberg Eriksen, Erik Skaaheim Haug, Bjørn Naume, Bjørn Møller
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Cancer patient pathways (CPPs) were implemented in 2015 to reduce waiting time, regional variation in waiting time, and to increase the predictability of cancer care for the patients. The aims of this study were to see if the nati
Externí odkaz:
https://doaj.org/article/2a3b37da840644dab4f585cacbab58d8
Autor:
Gustav Graabak, MS, Bjørn Henning Grønberg, MD, PhD, Marie Søfteland Sandvei, MD, PhD, Yngvar Nilssen, MSc, PhD, Tarje Onsøien Halvorsen, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100270- (2022)
Introduction: Twice-daily (BID) thoracic radiotherapy (TRT) of 45 Gy per 30 fractions is recommended for limited-stage (LS) SCLC, but most patients are treated with once-daily (OD) schedules owing to toxicity concerns and logistic challenges. An alte
Externí odkaz:
https://doaj.org/article/0b3cb34cf7da4e87aa4e7df0d11090d8
Publikováno v:
Acta Oncologica. 61:749-756
Long-term data on disease trajectory of EGFR-mutated early-stage non-small cell lung cancer (NSCLC) is still limited. This is relevant in the context of the recently approved introduction of adjuvant EGFR-targeting therapy, specifically osimertinib i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb58ef2d772952bdf09145301bb253fb
https://doi.org/10.1080/0284186x.2022.2066984
https://doi.org/10.1080/0284186x.2022.2066984
Publikováno v:
Cancers
Volume 15
Issue 5
Pages: 1505
Volume 15
Issue 5
Pages: 1505
Clinical studies have shown the efficacy of EGFR- and ALK-directed therapies in non-small cell lung cancer (NSCLC). Real-world data on, e.g., testing patterns, uptake, and duration of treatment are scarce. Reflex EGFR and ALK testing of non-squamous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b617400bf8a2041555da3000297838c
Publikováno v:
The European Journal of Public Health
Background International and national differences exist in survival among lung cancer patients. Possible explanations include varying proportions of emergency presentations (EPs), unwanted differences in waiting time to treatment and unequal access t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fba17bf4a5d0eed1180a52fad83be5c
https://doi.org/10.1093/eurpub/ckab071
https://doi.org/10.1093/eurpub/ckab071